Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest Down 93.6% in January

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) saw a large decrease in short interest in the month of January. As of January 15th, there was short interest totaling 2,155 shares, a decrease of 93.6% from the December 31st total of 33,566 shares. Based on an average daily trading volume, of 1,441 shares, the short-interest ratio is presently 1.5 days. Currently, 1.4% of the company’s shares are short sold. Currently, 1.4% of the company’s shares are short sold. Based on an average daily trading volume, of 1,441 shares, the short-interest ratio is presently 1.5 days.

Amplify Weight Loss Drug & Treatment ETF Stock Performance

NYSEARCA THNR traded up $0.18 on Thursday, hitting $26.30. 26,333 shares of the stock were exchanged, compared to its average volume of 2,633. Amplify Weight Loss Drug & Treatment ETF has a 52-week low of $18.56 and a 52-week high of $27.28. The firm has a market capitalization of $3.95 million, a P/E ratio of 24.31 and a beta of 0.61. The stock has a fifty day moving average price of $25.74 and a two-hundred day moving average price of $24.20.

Amplify Weight Loss Drug & Treatment ETF Dividend Announcement

The company also recently declared an annual dividend, which was paid on Wednesday, December 31st. Investors of record on Tuesday, December 30th were issued a dividend of $0.4132 per share. This represents a yield of 162.0%. The ex-dividend date was Tuesday, December 30th.

Institutional Trading of Amplify Weight Loss Drug & Treatment ETF

An institutional investor recently raised its position in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC grew its holdings in shares of Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) by 5.1% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 24,891 shares of the company’s stock after buying an additional 1,215 shares during the quarter. Jane Street Group LLC owned 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 at the end of the most recent reporting period.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.